Rivera-Franco MM, León-Rodríguez E

Language: English
References: 17
Page: 142-149
PDF size: 283.79 Kb.

ABSTRACT

Background: In 2004, a Universal Healthcare System was established in Mexico in order to protect most patients from catastrophic expenditures. Hematopoietic stem cell transplantation (HSCT) has been covered since 2015 at our center, a national health institute.
Objective: To analyze the impact of the Seguro Popular in HSCT in adults at one of the referral centers of this system.
Patients and Method: A retrospective analysis of patients undergoing HSCT with and without financing by the Seguro Popular at a national institute of health in Mexico City performed from January 2011 to December 2018.
Results: There were included 194 patients. The mean number of HSCT performed annually before and after Seguro Popular was similar. No differences were observed in non-relapse mortality. The 2-year disease-free survival and overall survival were similar before and after Seguro Popular for both, autologous and allogeneic/haploidentical HSCT.
Conclusions: Although Seguro Popular has eliminated some important expenses generated mainly by the in-patient procedure, it still has deficiencies that should be solved in order to achieve an optimal universal healthcare coverage in Mexico. Further studies should be performed focusing on other expenses and more importantly, the other two affiliated centers to the Seguro Popular should publish their results for further comparisons.

REFERENCES

1. Mexico-New Global Poverty Estimates. World Bank. https://databank.worldbank.org /data/download/ poverty/33EF03BB-9722-4AE2-ABC7-AA2972D68AFE/ Archives-2019/Global_POVEQ_MEX.pdf Accessed on June 6th, 2019.

2. Knaul FM, Arreola-Ornelas H, Mendez O. Financial protection in health: Mexico, 1992 to 2004. Salud Publica Mex 2005; 47: 430-9.

3. Frenk J, Gonzalez-Pier E, Gomez-Dantes O, Lezana MA, Knaul FM. Comprehensive reform to improve health system performance in Mexico. Lancet 2006; 368: 1524-34. doi: 10.1016/S0140-6736(06)69564-0

4. Strasser-Weippl K, Chavarri-Guerra Y, Villarreal-Garza C, Bychkovsky BL, Debiasi M, Liedke PE, et al. Progress and remaining challenges for cancer control in Latin America and the Caribbean. Lancet Oncol 2015; 16(14): 1405-38. doi: 10.1016/S1470-2045(15)00218-1

5. Xu K, Evans DB, Carrin G, Aguilar-Rivera AM, Musgrove P, Evans T. Protecting households from catastrophic health spending. Health Aff (Millwood) 2007; 26: 972-83. doi: 10.1377/hlthaff.26.4.972

6. Rivera Franco MM, Leon Rodriguez E, Castro Saldaña HL. Costs of hematopoietic stem cell transplantation in a developing country. Int J Hematol 2017; 106(4): 573-80. doi: 10.1007/s12185-017-2278-1

7. Rivera Franco MM, Leon Rodriguez E. Importance of non-governmental organizations for the establishment of a successful hematopoietic stem cell transplantation program in a developing country. J Glob Oncol 2018; 4: 1-8. doi: 10.1200/JGO.17.00091

8. Bleich SN, Cutler DM, Adams AS, Lozano R, Murray CJ. Impact of insurance and supply of health professionals on coverage of treatment for hypertension in Mexico: population based study. BMJ: British Medical Journal 2007; 335(7625): 875. doi: 10.1136/bmj.39350.617616.BE

9. Knaul FM, Arreola-Ornelas H, Mendez-Carniado O, Bryson- Cahn C, Barofsky JT, Maguire R, et al. Evidence is good for your health system: policy reform to remedy catastrophic and impoverishing health spending in Mexico. Lancet 2006; 368: 1828-41. doi: 10.1016/S0140-6736(06)69565-2

10. SSA: Frequently Asked Questions about Seguro Popular. Secretaría de Salud (SSA), Gobierno de México. http:// data.salud.cdmx.gob.mx/portal/seguro_popular/index/ preguntas.php. Accessed 11 December 2017.

11. King G, Gakidou E, Imai K, Lakin J, Moore RT, Nall C, et al. Public policy for the poor? A randomised assessment of the Mexican universal health insurance programme. Lancet 2009; 373: 1447-54. https://doi.org/10.1016/ S0140-6736(09)60239-7

12. Galárraga O, Sosa-Rubí SG, Salinas-Rodríguez A, Sesma- Vázquez S. Health insurance for the poor: impact on catastrophic and out-of-pocket health expenditures in Mexico. Eur J Health Econ 2010; 11(5): 437-47. doi: 10.1007/ s10198-009-0180-3.

13. Gakidou E, Lozano R, Gonzalez-Pier E, Abbott-Klafter J, Barofsky JT, Bryson-Cahn C, et al. Assessing the effect of the 2001–06 Mexican health reform: an interim report card. Lancet 2006; 368: 1920-35. https://doi.org/10.1016/ S0140-6736(06)69568-8

14. Perez-Rico R, Sesma-Vazquez S, Puentes-Rosas E. Catastrophic health expenditures in Mexico: comparative study by social exclusion level. Salud Publica Mex 2005; 47(Suppl 1): S47-S53.

15. Grogger J, Arnold T, León AS, Ome A. Heterogeneity in the effect of public health insurance on catastrophic out-ofpocket health expenditures: the case of Mexico. Health Policy Plan 2015; 30(5): 593-9. doi: 10.1093/heapol/czu037

16. Leon Rodriguez E, Rivera Franco MM. Outcomes of hematopoietic stem cell transplantation at a limited-resource center in Mexico are comparable to those in developed countries. Biol Blood Marrow Transplant 2017; 23(11): 1998-2003. doi: 10.1016/j.bbmt.2017.07.010

17. Reynoso-Noverón N, Villarreal-Garza C, Soto-Perez-de-Celis E, Arce-Salinas C, Matus-Santos J, Ramírez-Ugalde MT, et al. Clinical and epidemiological profile of breast cancer in Mexico: results of the Seguro Popular. J Glob Oncol 2017; 3(6): 757-64. doi: 10.1200/JGO.2016.007377